Page 625«..1020..624625626627..630640..»

Gene-editing, Moderna, and transhumanism | Christina Lin …

Posted: October 16, 2021 at 2:59 am

As gene-based mRNA vaccines from Moderna are being designed and tested at warp speeds to fight Covid-19, this is also bringing the debate over transhumanism into the forefront.

Transhumanism is a type of futurist philosophy aimed at transforming the human species by means of biotechnologies. Transhumanists see disease, aging and death as undesirable and unnecessary, and aim to transform human beings into post-human species with greater capacities than those of present human beings.

The philosophy is based on secular humanism and sees human nature as an evolutionary work-in-progress with room for improvement and enhancement. However, it is more radical in that it promotes not only traditional means of improving human nature such as education and cultural refinement, but also direct application of medicine and technology to overcome basic biological limits.

Transhumanists give special attention to genetic engineering, robotics, molecular nanotechnology and artificial intelligence, and the Covid-19 pandemic is providing gene-based vaccines a chance to break through into the global health market.

Moderna and gene-editing

Currently there are various companies such as Inovio, Moderna and CanSino Biologics that are testing mRNA and DNA vaccines to counter SARS coronavirus-2 (SARS CoV-2) which causes Covid-19, but Moderna is the front runner that recently nabbed $472 million from U.S. governments Biomedical Advanced Research and Development Authority (BARDA) to develop the vaccine. This is in addition to the $483 million it had already received back in April, bringing its total funding to $955 million.

With U.S. government funding at nearly $1 billion for one company, Moderna may be too big to fail. However, this is perplexing for a company that has never produced a single vaccine. According to a CNN report, Moderna was only established in 2010, has never brought a product to market, nor gotten any of its nine or so vaccine candidates approved for use by the FDA.

However, it has been a long-term Pentagon contractor for biodefense, working closely with Defense Advanced Research Project Agency (DARPA) on gene-editing and mRNA therapeutics. DARPA is focused on developing emerging disruptive technologies to maintain a competitive edge over adversaries, including many transhuman projects such as genetic engineering and soldier enhancement via robotics.

In the case of Moderna and mRNA therapeutics, DNA vaccines is considered a new paradigm that would disrupt the pharmaceutical industry. Its vision is to harness a new technology that synthesizes messenger RNA, or mRNAwhich is an instruction manual in every living cell for creating proteinto prompt the human body to make its own medicine.

So instead of injecting a piece of virus into a person to stimulate the immune system, the synthesized genes would be shot into the body whereby the genes are edited, deleted, added, to re-engineer human DNA to resist the disease. If successful, scientists hope DNA vaccines could be a transformative treatment for heart disease, metabolic and genetic diseases, kidney failure and even cancer. Moreover, it could be an effective form of biodefense to protect the population against biological warfare, which is also the mandate for DARPA and BARDA.

Transhumanism and hybrids

Indeed, DARPA is also developing other forms of human enhancement in addition to gene editing. Already scientists are merging robotics with the human body in brain-to-computer interface (BCI), wherein individuals with physical injuries can regain their functions, and soldiers become smarter and more powerful through the fusing of their brain with machines.

In a way, the Pentagon is now building real iron man similar to the American superhero based on the Marvel Comics character. Soldiers in exoskeleton suits are physically more powerful than those without, while other soldiers with bionic limbs perform better than adversaries with human limbs. When one adds artificial intelligence with BCI, the sky is the limit for an army of these genetically modified and robotically enhanced humanoids.

But U.S. is not the only country engaged in human enhancement and transhumanism, as Russia and China are also in hot pursuit with exoskeletons, vaccines and brain implants. As this competition gains traction, one wonders what the future of their militaries may look like as human beings are steadily integrated with machines to become armies of iron man.

Here the Book of Daniel may lend some insights. In interpreting King Nebuchadnezzars dream of an image with a head of gold, chest and arms of silver, belly and thighs of bronze, legs of iron, and feet of iron and clay, Daniel revealed the parts as the sequence of world empires, with the feet of iron and clay being the last.

King Nebuchadnezzars dream manDaniel 2

All Telugu Christian Songs Lyrics - , 5 2016

In Daniel 2:43 it is written, as you saw iron mixed with ceramic clay, they will mingle with the seed of men; but they will not adhere to one another, just as iron does not mix with clay, that seems to describe a hybrid of man (clay) mixed with machine (iron). And as transhumanism and biotech gain momentum, armies of hybrid humans of iron and clay may be a real possibility in a not too distant future world.

Dr. Christina Lin is a US-based foreign policy analyst specializing in China-Mediterranean relations. She has extensive US government experience working on national security issues and was a CBRN (chemical, biological, radiological, nuclear) research consultant for Jane's Information Group.

Read the original post:
Gene-editing, Moderna, and transhumanism | Christina Lin ...

Posted in Transhumanism | Comments Off on Gene-editing, Moderna, and transhumanism | Christina Lin …

COVID19, The Great Reset, and Transhumanism Thuletide

Posted: October 16, 2021 at 2:59 am

Quick update with recent news. Ill probably write a better article at some point, but this will do for now. I still havent thought of a new name for an optics-friendly blog, otherwise Id put this stuff on there.

Also adding new Great Reset category to the site.

CONTENTS

As Im sure many of you are already aware, globalist elites are using their COVID19 psyop to push through The Great Reset, which is simply a rebranding of the United Nations Agenda 21 (also known as Agenda 2030 and Sustainable Development Goals).

The Great Reset was known as Agenda 21 while globalists were using Global Warming as the primary psyop excuse for creating a one-world government, The Great Reset is merely the virus psyop rebrand.

When Globalists say things like:No poverty!Good health!Zero hunger!

Theyre telling you that they plan to take totalitarian control over that aspect of humanity, and will micromanage it like the neurotic freaks that they are. They obviously dont care about poverty, hunger, etc., they just want power. Same deal when they talk about World Peace. Any conflict that they havent personally engineered causes instability and factionalism that threatens their global dominance. They dont actually want World Peace, they want a monopoly and violence, and to transform you into a pacifist cuck who kisses their boots while they stomp on your neck.

What the Great Reset is bringing us is what the globalist (or United Nations) agenda has always been: Global Communism. Dont forget that the four pillars of Communism, as laid out in Marx Communist Manifesto, are:

Anyway,themajor aspect of The Great Reset is the digitization of humanity. In other words, they aim to force transhumanism onto the entire human population or the populace of the West, at least. In the words of the sinister Great Reset faceman, Klaus Schwab, they aim to [fuse] our physical, digital and biological identity.

The transhumanist agenda dates back to the early 1900s, and globalists such as UNs Julian Huxley, who coined the term.

Unfortunately, the history of transhumanism is too long and complex to get into here, but the fusion of man with machine has always been on the globalist cards. However, their aim is not to use technology to make the masses of humanity into superhuman cyborgs, but to use technology to transform the masses of humanity into easily controlled slave gimps.

As explained by Julian Huxleys brother, Aldous (who authored Brave New World, a dystopian fiction novel), the globalists aim is to transform the world into a painless concentration camp in which pharmacological methods will make people love their servitude.

We effectively already have this with anti-depressants and so on, which are designed to stop you from feeling shitty about having such a wretched, soulless society, and kick your ass back into the meatgrinder so you can wagecuck like a good little debt slave. Around 20% of Americans are on psychiatric pharmaceuticals. Normies think that this is becausewe simply have a better understanding of mental health now,and not because society is disgusting and everyone fucking hates it.

The final step is to technologically regulate human behavior via transhumanism. Simply put, theyre going to put microchips in your brain and frazzle your thoughts. They already have the technology. (I know it sounds wacky, but you can look all if this up yourself. Its real).

So, how do globalists plan to achieve this?

Well, if youve seen the Great Reset primer image that was handily created for us by the World Economic Forum, youll have noticed that it includes things like:

The World Economic Forum, which is part of the United Nations network, very recently announced the release of a digital identity app, you can read the details in the second image below, which is higher res. The digital identity agenda will likely be the wedge issue that globalists use to force transhumanism upon the masses.

This is where the virus psyop comes in.

Globalists claim that the functionally useless lockdowns are an absolute necessity to combat the 99%-survival-rate virus. In reality, they are being used to break the will of the public and irreparably destroy the final few freedoms people have left. The middle class has been devastated, while global elites are more powerful than ever.

There are massive protests all across the West in response to the lockdowns, though these will soon be met with violent oppression from the globalist-puppeteered governments.

It is likely that people will be banned from travel, shopping, socializing, etc., unless theyre vaccinated. Some sort of digital chip may be implanted alongside the vaccine, which will be used to prove the individuals vaccinated status (tagged and bagged with a slave stamp).

This may be the beginning of the individuals digital identity, with the excuse that they must be loaded into a virus-free database.

The technology to do this has already been patented by none other than the Bill Gates Foundation.

As with the lockdowns, many people will resist the digitization of humanity and the transhumanist project as a whole. However, many more will embrace it with open arms.

For the digitization of humanity to be successful, elites will have to create a significant distinction between the digitized and non-digitized. Perhaps the virus will play a role, those who are not vaccinated may be treated as inhuman and socially ostracized, though it is more likely that non-vaccinated people will simply be refused access to basic services within society, as outlined above. This will create a pariah caste, who are completely unable to function in the newly digitized world.

Eventually, the masses will be so distraught and demoralized by lockdown life that they will beg to be vaccinated.

Get the vaccine, Leftoid. You dont want to be one of those racist, bigots, do you?

The success of the transhumanist project is also reliant upon the creation of a one-world digital currency, that will undoubtedly be linked to these digital identities. The creation of a one-world currency is something that elites have talked about for decades.

An article from the Rothschild-owned Economist paper:

Many elites, such as Bill Gates, have invested in and endorsed digital currency:

We may see the implementation of UBI, linked to some sort of Communist China-style social credit system. ThisForbes articlestates that the Federal Reserve has plans to create a digital dollar and a digital dollar wallet via the U.S Treasury, which was suggested to provide economic stimulus benefits and possibly universal basic income to Americans.

Facebooks Tel Aviv team are working on a digital wallet:

The Jerusalem Post stated that a global collapse would be a way to wipe the slate clean of nation-based currencies, especially the US dollar, and establish an international one: like bitcoin.

Klaus Schwab has ominously warned (threatened?) that there may be a Cyber Pandemic (what does this even mean?) that will be worse than COVID. How will this convince the masses that a digital identity and one-world digital currency is a good idea? I dont know.

Wolfish (who makes good YouTube videos, check him out) guesses that the Cyber Pandemic may be used to create a one-world digital currency, which would require the United Nations digital identity to use.

The final and most disturbing thing that Ive learned of recently is this patent, which seems to be for some sort of device that would essentially transform an individual into a human bitcoin mining device. I havent looked into it fully, but it seems to be style biological energy harvesting a la The Matrix. So, yeah, were heading towards some really fucked up shit here.

Like Loading...

Related

Follow this link:
COVID19, The Great Reset, and Transhumanism Thuletide

Posted in Transhumanism | Comments Off on COVID19, The Great Reset, and Transhumanism Thuletide

Rheumatoid Arthritis Stem Cell Therapy Market By Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant, Adipose Tissue Stem Cells) and By…

Posted: October 16, 2021 at 2:56 am

250 Pages Rheumatoid Arthritis Stem Cell Therapy Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider

Rheumatoid arthritis stem cell therapy has been demonstrated to induce profound healing activity, halt arthritic conditions, and in many cases, reverse and regenerate joint tissue. Today, bone marrow transplant, adipose or fat-derived stem cells, and allogeneic mesenchymal stem cells (human umbilical cord tissue) are used for rheumatoid arthritis stem cell therapy.

The Market Research Survey by Fact.MR, highlights the key reasons behind increasing demand and sales of Rheumatoid Arthritis Stem Cell Therapy.Rheumatoid Arthritis Stem Cell Therapy market driversand constraints, threats and opportunities, regional segmentation and opportunity assessment, end-use/application prospects review are addressed in the Rheumatoid Arthritis Stem Cell Therapy market survey report. The survey report provides a comprehensive analysis of Rheumatoid Arthritis Stem Cell Therapy market key trends and insights on Rheumatoid Arthritis Stem Cell Therapy market size and share.

To Get In-depth Insights Request for Brochure here https://www.factmr.com/connectus/sample?flag=B&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market: Segmentation

Tentatively, the global rheumatoid arthritis stem cell therapy market can be segmented on the basis of treatment type, application, end user and geography.

Based on treatment type, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on application, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on distribution channel, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Key questions answered in Rheumatoid Arthritis Stem Cell Therapy Market Survey Report:

Request Customized Report as Per Your Requirements https://www.factmr.com/connectus/sample?flag=RC&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market: Key Players

The global market for rheumatoid arthritis stem cell therapy is highly fragmented. Examples of some of the key players operating in the global rheumatoid arthritis stem cell therapy market include Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, TiGenix and others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

Essential Takeaways from the this Market Report

Enquire Before Buying Here https://www.factmr.com/connectus/sample?flag=EB&rep_id=1001

The Report Covers Exhaustive Analysis On:

Explore Fact.MRs Coverage on theHealthcareDomain:

Hemostasis Valves MarketAccording to the latest research by Fact.MR, the Hemostasis Valves Market is set to witness steady growth during 2021-2031. The increasing advancement in the hemostasis valves industry will offer lucrative opportunities and an increasing number of interventional procedures is propelling the market growth.

Cosmetic Dentistry MarketThe global cosmetic dentistry market is estimated to witness significant growth during the forecast period of 2021-2031. This growth is factored in due to the rising consumer awareness and well-defined grooming interest in the aesthetical value of oral care.

Creatinine Testing MarketCreatinine testing involves the measurement of the level of creatinine, which is a product of muscle creatine catabolism and is thus a reliable indicator of kidney function by an indication that a rise in the level of creatinine may indicate Acute Kidney Injury or Chronic Kidney Disease.

About Fact.MR

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and well be an able research partner.

Contact:US Sales Office:11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E-Mail:[emailprotected]

Corporate Headquarter:Unit No: AU-01-H Gold Tower (AU),Plot No: JLT-PH1-I3A,Jumeirah Lakes Towers,Dubai, United Arab Emirates

The post Rheumatoid Arthritis Stem Cell Therapy Market By Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant, Adipose Tissue Stem Cells) and By Application (Rheumatoid Arthritis Stem Cell Therapy) Forecast to 2021-2031 appeared first on The Swiss Times.

Read the original here:
Rheumatoid Arthritis Stem Cell Therapy Market By Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant, Adipose Tissue Stem Cells) and By...

Posted in Stem Cell Therapy | Comments Off on Rheumatoid Arthritis Stem Cell Therapy Market By Type (Allogeneic Mesenchymal Stem Cells, Bone Marrow Transplant, Adipose Tissue Stem Cells) and By…

Worldwide Cell Therapy Consumables Industry to 2031 – Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others – PRNewswire

Posted: October 16, 2021 at 2:56 am

DUBLIN, Oct. 12, 2021 /PRNewswire/ -- The "Cell Therapy Consumables Market by Type of Consumable, Type of Cell Therapy, Scale of Operation, Type of End-User and Key Geographical Regions: Industry Trends and Global Forecasts, 2021 - 2031" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market.

According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains.

Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents.

Presently, over 60 service providers are actively engaged in providing consumable/raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and/or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.

Amongst other elements, the report features:

Key Questions Answered

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE4.1. Chapter Overview4.2. Cell Therapy Kit Providers: List of Players4.3. Cell Therapy Media Providers: List of Players4.4. Cell Therapy Reagent Providers: List of Players4.5. Analysis by Type of Consumable, Type of Cell Therapy and Application Area (Grid Representation)

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Key Assumptions and Parameters5.3. Methodology5.4. Company Competitiveness: Kit Providers5.5. Company Competitiveness: Media Providers5.6. Company Competitiveness: Reagent Providers

6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS6.1. Chapter Overview6.2. Scope and Methodology6.3. Bio-Techne6.4. Miltenyi Biotec6.5. Sartorius6.6. STEMCELL Technologies6.7. Thermo Fisher Scientific

7. COMPANY PROFILES7.1. Chapter Overview7.2. Miltenyi Biotec7.2.1. Company Overview7.2.2. Product Portfolio7.2.3. Recent Developments and Future Outlook7.3. STEMCELL Technologies7.3.1. Company Overview7.3.2. Product Portfolio7.3.3. Recent Developments and Future Outlook7.4. Bio-Techne7.4.1. Company Overview7.4.2. Product Portfolio7.4.3. Recent Developments and Future Outlook7.5. Irvine Scientific7.5.1. Company Overview7.5.2. Product Portfolio7.5.3. Recent Developments and Future Outlook7.6. Thermo Fisher Scientific7.6.1. Company Overview7.6.2. Product Portfolio7.6.3. Recent Developments and Future Outlook7.7. Sartorius7.7.1. Company Overview7.7.2. Product Portfolio7.7.3. Recent Developments and Future Outlook7.8. BD Biosciences7.8.1. Company Overview7.8.2. Product Portfolio7.8.3. Recent Developments and Future Outlook7.9. Lonza7.9.1. Company Overview7.9.2. Product Portfolio7.9.3. Recent Developments and Future Outlook7.10. CellGenix7.10.1. Company Overview7.10.2. Product Portfolio7.10.3. Recent Developments and Future Outlook7.11. Corning7.11.1. Company Overview7.11.2. Product Portfolio7.11.3. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS AND INITIATIVES8.1. Chapter Overview8.2. Partnership Models8.3. Cell Therapy Consumables: Recent Partnerships and Collaborations8.4. Cell Therapy Consumables: Recent Expansions

9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS 9.1. Chapter Overview9.2. Scoring Criteria and Key Assumptions9.3. Scope and Methodology9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers9.3.1. Likely Partner Opportunities for Dendritic Cell Therapy Consumable Providers9.3.2. Likely Partner Opportunities for NK Cell Therapy Consumable Providers9.3.3. Likely Partner Opportunities for Stem Cell Therapy Consumable Providers9.3.4. Likely Partner Opportunities for T-Cell Therapy Consumable Providers

10. DEMAND ANALYSIS10.1. Chapter Overview10.2. Scope and Methodology10.3. Global Demand for Cell Therapy Consumables10.4. Global Demand for Cell Therapy Consumables for Planar Processes10.5. Global Demand for Cell Therapy Consumables for Suspension Processes10.6. Analysis by Scale of Operation10.7. Analysis by Region

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS11.1. Chapter Overview11.2. Forecast Methodology11.3. Global Outsourced Cell Therapy Consumables Market, 2021-203111.4. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Consumable11.5. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Cell Therapy11.6. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Scale of Operation11.7. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of End-User11.8. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Geography

12. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES12.1. Chapter Overview12.2. Emerging Trends Related to Cell Culture Media12.3. Automation of Cell Therapy Manufacturing Processes12.4. Single Use Systems and Technologies in Cell Therapy Manufacturing

13. IMPACT OF COVID-19 ON CELL THERAPY CONSUMABLES MARKET13.1. Chapter Overview13.2. Impact of COVID-19 Pandemic on Cell Therapy Consumables Market13.3. Impact on Future Market Opportunities for Cell Therapy Consumable Providers13.4. Current Opinions and Key Initiatives of Key Players13.5. Recuperative Strategies for Developer Businesses13.5.1. Strategies for Implementation in the Short / Mid Term13.5.2. Strategies for Implementation in the Long Term

14. CONCLUDING REMARKS14.1. Chapter Overview

15. INTERVIEW TRANSCRIPTS15.1. Chapter Overview15.2. Anant Kamath, Chief Operating Officer, Cellular Engineering Technologies15.2.1. Cellular Engineering Technologies: Key Highlights15.2.2. Interview Transcript15.3. Vishal G. Warke, Director R&D, Cell Culture and Immunology, HiMedia Laboratories and Gauri W. Page, Assistant R&D Manager, Animal Cell Culture, Himedia Laboratories15.3.1. HiMedia Laboratories: Key Highlights15.3.2. Interview Transcript

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/2t5jj1

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Follow this link:
Worldwide Cell Therapy Consumables Industry to 2031 - Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others - PRNewswire

Posted in Stem Cell Therapy | Comments Off on Worldwide Cell Therapy Consumables Industry to 2031 – Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others – PRNewswire

Caring Cross to Lend Insight to "Democratization of Access to Transformative Cell and Gene Therapies" Panel at Meeting on the Mesa 2021 -…

Posted: October 16, 2021 at 2:56 am

GAITHERSBURG, Md., Oct. 13, 2021 /PRNewswire/ --Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, announced that its Co-founder and Executive Director Boro Dropuli, Ph.D., M.B.A., will be a featured participant in the "Democratization of Access to Transformative Cell and Gene Therapies" panel at the Meeting on the Mesa 2021 conference in Carlsbad, CA. The annual meeting brings together senior executives and top decision-makers in the industry to advance cutting-edge research into and address commercialization opportunities involving cell and gene therapy.

Details of the presentation are as follows:

Panel:

"Democratization of Access to Transformative Cell and Gene Therapies"

Event:

Meeting on the Mesa 2021

Date:

Wednesday, October 13, 2021

Time:

7:15-8:45 a.m. PT

Registration:

Registration

"The clinical successes of CAR-T cell and other gene-therapies has opened the possibility for developing curative therapies for many diseases," Dr. Dropuli said. "However, the current price of such therapies limits patient access, particularly in underserved and less-developed communities around the world. It is important that both non-profit and for-profit stakeholders work together to lower the cost of such therapies with business models that are impactful, sustainable and bring value to investors and stakeholders alike."

Caring Cross recently launched its first initiative focused on CAR-T cell therapy utilizing manufacturing and distribution models that enable affordability and accessibility of these therapies to diverse patient populations and treatment indications. The non-profit aims to provide opportunities for both non-profit and for-profit innovators to change the way advanced medicines, like CAR-T cell therapies, are developed and how they are provided to patients in need.

In support of this endeavor, Caring Cross has created a community of highly experienced scientists, entrepreneurs and community advocates that are currently working with more than 100 clinical sites around the world to enable affordable and sustainable place-of-care manufacturing of CAR-T cells, with outstanding clinical results observed thus far.

Among Caring Cross' affiliations is the Global Gene Therapy Initiative (GGTI), which was formed in 2020 to tackle the barriers to low-and middle-income countries (LMIC) inclusion in gene therapy development and includes diverse stakeholders from all sectors. GGTI has set a goal of introducing two gene therapy Phase I clinical trials in two LMIC, Uganda and India, by 2024.

GGTI recently published a paper in Gene Therapy entitled, "Working Group Report for the Global Gene Therapy Initiative (GGTI)," that points to the massive gap between the companies, clinics, and researchers developing advanced therapeutic approaches and their availability to the patients who need them. The paper details the geographic exclusion of LMIC in gene therapy development and patients' lack of access to gene therapies in these areas, particularly for HIV infection and hemoglobinopathies global health crises impacting tens of millions of people primarily located in LMIC.

Caring Cross was also recently awarded a grant from the Bill and Melinda Gates Foundation to support the GGTI program for training of personnel from the Joint Clinical Research Center (JCRC) in Uganda on the methods for manufacturing gene-modified cell products. The training will occur at the Fred Hutchinson Cancer Research Center in Seattle under the direction of Dr. Jennifer Adair.

"The Global Gene Therapy Initiative, or GGTI, is an alliance of scientists, engineers, clinical investigators and community advocates that aim to accelerate access to validated gene therapies in low- and middle-income countries, by grassroots community involvement, fostering education and training, infrastructure development and implementation of clinical trials," Dr. Adair said. "Our goal is to implement clinical trials in countries like Uganda and India by 2024."

Dr. Cissy Kityo, Executive Director of the JCRC, commented: "We are pleased to receive support from the Bill and Melinda Gates Foundation to train our personnel on how to manufacture gene-modified cell therapy products locally at our facilities and plan to implement clinical trials in the future targeting diseases such as HIV and Sickle Cell Disease."

About Caring CrossCaring Cross is a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and ensuring access to cures for all patients, everywhere. To enable its mission, Caring Cross is mobilizing a growing community of healthcare professionals, scientists, engineers, community advocates, donors, investors and business leaders to support the development of technologies and candidate medicines and technologies. Currently, Caring Cross is advancing several initiatives that aim to improve the accessibility, affordability and applicability of CAR-T technology and stem cell gene therapy. These opportunities include developing and implementing affordable solutions for the manufacture of CAR-T cells, advancing a decentralized, place-of-care cell manufacturing model, and developing its first therapeutic candidate, an anti-HIV duoCAR-T cell therapy designed to suppress HIV replication and eliminate HIV-expressing cells in people with HIV. A stem cell gene therapy for Sickle Cell Disease and Beta-Thalassemia is also in development. For more information on Caring Cross visit https://caringcross.org/.

CONTACTTiberend Strategic Advisors, Inc.InvestorsLisa Sher970-987-2654 [emailprotected]

Media Ingrid Mezo646-604-5150 [emailprotected]

SOURCE Caring Cross

http://www.caringcross.org

Go here to see the original:
Caring Cross to Lend Insight to "Democratization of Access to Transformative Cell and Gene Therapies" Panel at Meeting on the Mesa 2021 -...

Posted in Stem Cell Therapy | Comments Off on Caring Cross to Lend Insight to "Democratization of Access to Transformative Cell and Gene Therapies" Panel at Meeting on the Mesa 2021 -…

Why Jasper Therapeutics Stock Is Soaring Today – Yahoo Finance

Posted: October 16, 2021 at 2:56 am

Jasper Therapeutics Inc (NASDAQ: JSPR) is surging higher Wednesday after Oppenheimer analyst Jay Olson initiated coverage on the stock with an Outperform rating and announced a price target of $21.

The Oppenheimer analyst cited the potential of Jasper Therapeutics' conditioning agents for hematopoietic stem cell transplantation.

Jasper Therapeutics went public via special purpose acquisition company Amplitude Healthcare Acquisition Corporation at the end of September.

Jasper Therapeutics is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It's focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

JSPR Price Action: Jasper Therapeutics is making new 52-week highs during Wednesday's trading session.

The stock was up about 111% at $15.27 per share at time of publication.

Latest Ratings for JSPR

Oct 2021

Oppenheimer

Initiates Coverage On

Outperform

View More Analyst Ratings for JSPR View the Latest Analyst Ratings

See more from Benzinga

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original here:
Why Jasper Therapeutics Stock Is Soaring Today - Yahoo Finance

Posted in Stem Cell Therapy | Comments Off on Why Jasper Therapeutics Stock Is Soaring Today – Yahoo Finance

Why Jasper Therapeutics Stock Is Falling Today – Benzinga

Posted: October 16, 2021 at 2:56 am

Jasper Therapeutics Inc (NASDAQ: JSPR) is trading lower Thursday amidprofit taking after the stock rallied roughly 120% on Wednesday.

Jasper Therapeuticssurgedhigher Wednesday afterOppenheimer analyst Jay Olson initiatedcoverage on the stockwith anOutperform rating and announced aprice target of$21.

The Oppenheimer analyst cited the potential of Jasper Therapeutics' conditioning agents for hematopoietic stem cell transplantation.

Jasper Therapeutics went public via special purpose acquisition companyAmplitude Healthcare Acquisition Corporation at the end of September.

Jasper Therapeuticsis a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It'sfocused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

JSPR Price Action:Jasper Therapeutics was down 16% at $12.42 at time of publication.

View More Analyst Ratings for JSPR View the Latest Analyst Ratings

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View post:
Why Jasper Therapeutics Stock Is Falling Today - Benzinga

Posted in Stem Cell Therapy | Comments Off on Why Jasper Therapeutics Stock Is Falling Today – Benzinga

Breast Cancer symptoms, prevention, and treatment – NewsPatrolling

Posted: October 16, 2021 at 2:56 am

Breast cancer is the most common cancer diagnosed among women in India. Breast cancer occurs in both sex but in male it accounts for less than 1% of all cases of breast cancer. It is treatable if diagnosed early. Localized cancer can generally be treated before it spreads outside the breast. But once the cancer begins to spread, treatment becomes more complicated. Early detection, better approach to treatment and better understanding of the disease has led to increased survival rates and decreased death rate.

Breast cancer usually begins either in your glands that make milk known as lobular carcinoma or the ducts that carry it to the nipple called ductal carcinoma. It can grow larger in your breast and spread to nearby lymph nodes or through your bloodstream to other organs.

The most common symptom of breast cancer is growth of a lump which is a painless, hard mass that has irregular edges. They can even be painful. It is always important to have breast mass, lump, or breast change checked by a specialist.

Other symptoms to watch out are:

Lump or thickening of breast

Change in size shape or appearance of breast

Changes to the skin, indrawing of nipple or ulceration of skin

Redness or roughness of skin over breast

Nipple discharge that can be bloody or clear

These changes may be noticed while performing monthly breast self-exams. By performing breast self-exams, you will become familiar with the normal monthly changes in your breasts.

Risk factors include:

Increasing age

Personal history of breast cancer

Personal history of breast condition like LCIS or Atypical hyperplasia

Family history

Inherited genes

Radiation exposure

Obesity

Early menarche

Age at first childbirth childbirth after 30yrs have increased risk breast cancer

Post-menopausal hormone therapy

Alcohol consumption

There is no definite way to prevent breast cancer. But there are things that can help in lowering the risk such as changing risk factors that can be controlled by making certain changes in daily life to help reduce risk of breast cancer

Breast self-examination for breast awareness women may become familiar with their breast. If there is new change, lump or unusual sign doctor consultation should be taken promptly.

Clinical breast examination

Breast screening by mammography in women above 50yrs

Limitation of alcohol consumption

Daily exercise of at least 30 mins

Limit use of post-menopausal hormone therapy risk and benefit should be discussed with doctor in women who experience bothersome sign and symptoms of menopause.

BMI maintain a healthy weight, reduction in calorie intake and increase in exercise reduces the risk

Healthy diet extra virgin olive oil and mixed nuts Mediterranean diet like fruits, vegetables, whole grains, legumes reduce the risk of breast cancer

Breast cancer is diagnosed during a physical exam, by a self-examining the breasts, mammography, ultrasound testing, and biopsy. Women should begin annual breast screening between 40-44 years of age. Women aged 45 and older should have a screening mammogram every year.

Treatment depends on several factors, including the type and stage of cancer, persons sensitivity to hormones, age, overall health of the individual and other medical conditions. Treatment generally follows within a few weeks after the diagnosis. Breast cancer diagnosis and treatment are best achieved by a team of experts. The specialist needs to evaluate the advantages and limitations of each type of treatment for each patient to develop the best approach.

Chemotherapy, Neoadjuvant chemotherapy, Radiotherapy, Mastectomy, Conservative breast cancer surgery, Adjuvant systemic therapy and Hormone therapy are certain options used to treat breast cancer.

A variety of things influence breast cancer risk including family history and other known risk factors. Screening can help catch it early and the earlier its diagnosed, the more treatable it is. The longer it takes to diagnose a breast cancer, the more difficult treatment becomes.

BY: Dr. Amitesh Anand, Surgical Oncologist, HCG Abdur Razzaque Ansari Cancer Hospital Ranchi

Read more from the original source:
Breast Cancer symptoms, prevention, and treatment - NewsPatrolling

Posted in HCG Diet | Comments Off on Breast Cancer symptoms, prevention, and treatment – NewsPatrolling

Durham firm offering up to $10,000 for researchers to use its intestinal technology – WRAL Tech Wire

Posted: October 16, 2021 at 2:53 am

RESEARCH TRIANGLE PARK Durham-basedAltis Biosystemsis offering a research award of up to $10,000 for a scientific team to use its proprietary drug-development technology in a research project.

Altis is soliciting proposals from company and academic scientists to use RepliGut, its patented platform that replicates the intestinal epithelium, the thin layer of cells that line the small and large intestines and are vital to good health.

Altis has always been at the forefront of innovative and more-biologically relevant research to enable the development of more effective drugs, said Michael Biron, the companys chief executive officer. We view this research award as a way to further this development with partners to produce meaningful and informative scientific experiments to advance their pipelines.

.The use of RepliGut will also help Altis gather feedback on the technology to help broaden its applications, said Niki Heinz, director of business development at Altis.

We have this really unique technology, Heinz said. As many brains as we can have working on this in terms of what people want to do with it, the better.

Interested researchers working in drug discovery, safety, immunology, and inflammation can propose a project with RepliGut by completinga form on the companys websiteby Nov. 15.A project will be chosen by Dec. 10, and work will get under way by Jan. 15, 2022.

Potential applicants can gather more information about RepliGut by viewing an Oct. 12webinarfeaturing Bill Thelin, Ph.D., chief scientific officer at Altis. Thelin will address how intestine-on-a-chip technology can reliably model gastrointestinal disease and help researchers screen for safe, effective therapeutic candidates.

.RepliGut recreates the human intestinal epithelium in a high-throughput format for more biologically relevant screening of compounds, disease modeling and microbiome research.

Altis sells RepliGut as a kit and also provides a variety of contract research services for customers involving inflammation, barrier function, toxicology and drug disposition.

Intestinal stem cells used for the RepliGutsystem are harvested from transplant-grade human donor tissue for which there is no recipient match. Compounds and other cell types interact with the epithelial cells in a multi-well plate format that allows for high-throughput screening and integration with standard laboratory equipment and workflows.

With this design, RepliGutcan model different behaviors in the intestine, such as the barrier function, more accurately than typical methods that use cancer cell lines or animal models.

The companys goal for RepliGut is to reduce the time and cost of drug development with a platform that more closely represents native human biology and to reduce the need for animal testing.

RepliGuts core use is for screening drug compounds, but its utility is expanding to include gene expression and other downstream assays, Heinz said. Altis this summer hired Thelin as chief scientific officer to help broaden the platforms capacity.

The RepliGut technology was developed in the Biomedical Engineering Department at the University of North Carolina at Chapel Hill, and Altis was formed in 2017 to commercialize it.

Last August Altis raised $3.1 million in a seed series investment that was oversubscribed by nearly 50 percent. The round was led by VentureSouth of Greenville, S.C., and also involved local investors including RTP Capital and Hatteras Ventures, as well as other syndicate partners across the country including Atlanta Technology Angels and Central Texas Angel Network.

Altis declined to disclose its employment total but is adding staff to further develop RepliGut.

We have been hiring for the last month or so and continue to look for talent, Heinz said.

The company recently hiredseveral scientists to keep up with customer projectsand now is looking for a senior director of operations. It will be seekingadditionalscientists in the next couple of months, she said, as the company looks to expand its offerings to the research community.

See the original post:
Durham firm offering up to $10,000 for researchers to use its intestinal technology - WRAL Tech Wire

Posted in Texas Stem Cells | Comments Off on Durham firm offering up to $10,000 for researchers to use its intestinal technology – WRAL Tech Wire

ASU professor researches origins of Alzheimers to find a cure – Eight, Arizona PBS

Posted: October 16, 2021 at 2:52 am

ASU Associate Professor Dr. David Brafman is using personalized medicine to study the origins of Alzheimers. Dr. Brafman is tracing the origins of Alzheimers as a way to reprogram stem cells and potentially find a cure for the disease. We recently spoke to Dr. Brafman about his research.

What we use to model this disease is a special type of Stem cell called induced pluripotent stem cells and these cells are derived from patients and reprogram cells to essentially take on the characteristics of early development, Brafman said.

Brafman says this type of research can help his lab find the origins of the disease. He also says this research can help identify why some people are more predisposed to develop this disease, as well as commonalities between those who develop it.

A difficult aspect of treating Alzheimers is that by the time many develop noticeable symptoms, treatment becomes very difficult.

What were trying to identify is genetic diagnostic markers that might have profiles that predispose them towards Alzheimers disease so we could maybe introduce therapeutic interventions earlier, Brafman said

Another therapeutic strategy thought about is potentially swapping the harmful genes that lead to Alzheimers for less harmful ones. Brafman said his lab is looking at the potential for genome editing and genetic risk factors that may lead to the disease.

Brafman said this research could be used to trace the origins of other diseases down the road as well, and not just Alzheimers.

Read this article:
ASU professor researches origins of Alzheimers to find a cure - Eight, Arizona PBS

Posted in Arizona Stem Cells | Comments Off on ASU professor researches origins of Alzheimers to find a cure – Eight, Arizona PBS

Page 625«..1020..624625626627..630640..»